Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 16/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706519 | 0.85 | PIK3C3 (0.56) | GSK3BDYRK1AWNT1 | |
| SCHEMBL20733158 | 0.82 | ADORA3 (0.39) | GSK3BDYRK1AWNT1ADORA3ADORA2A | |
| SCHEMBL19699524 | 0.80 | ADORA3 (0.50) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19728661 | 0.78 | NPC1 (0.39) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19699517 | 0.76 | ADORA1 (0.44) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19699594 | 0.75 | DYRK1A (0.43) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19699596 | 0.75 | CDC7 (0.46) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19699527 | 0.75 | GSK3B (0.47) | GSK3BDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24932350 | 0.75 | EGFR (0.61) | GSK3BNPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL19699534 | 0.74 | MAPT (0.59) | NPC1RAB9ASMN1; SMN2TYK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2322/4885DYRK1A 3048/4885NPC1 3073/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885NPC1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.